Difference between revisions of "Larotrectinib (Vitrakvi)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
|||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*11/26/2018: Granted accelerated approval for adult and pediatric patients with [[:Category:Malignant solid neoplasm|solid tumors]] that have a [[Biomarkers#NTRK|neurotrophic tyrosine receptor kinase (NTRK) gene]] [[Biomarkers#Rearrangement|fusion]] without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment. | *11/26/2018: Granted accelerated approval for adult and pediatric patients with [[:Category:Malignant solid neoplasm|solid tumors]] that have a [[Biomarkers#NTRK|neurotrophic tyrosine receptor kinase (NTRK) gene]] [[Biomarkers#Rearrangement|fusion]] without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment. | ||
| + | |||
| + | == Patient Drug Information== | ||
| + | *[https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf Larotrectinib (Vitrakvi) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf Larotrectinib (Vitrakvi) Package Insert]</ref> | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' LOXO-101 | *'''Code name:''' LOXO-101 | ||
*'''Brand name:''' Vitrakvi | *'''Brand name:''' Vitrakvi | ||
| + | |||
| + | ==References== | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 11:33, 4 April 2021
General information
Class/mechanism from the NCI Drug Dictionary: An orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
History of changes in FDA indication
- 11/26/2018: Granted accelerated approval for adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment.
Patient Drug Information
Also known as
- Code name: LOXO-101
- Brand name: Vitrakvi